CCAAT/enhancer-binding protein delta regulates the stemness of glioma stem-like cells through activating PDGFA expression upon inflammatory stimulation.


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
12 Jul 2019
Historique:
received: 16 01 2019
accepted: 01 07 2019
entrez: 14 7 2019
pubmed: 14 7 2019
medline: 14 1 2020
Statut: epublish

Résumé

The small population of glioma stem-like cells (GSCs) contributes to tumor initiation, malignancy, and recurrence in glioblastoma. However, the maintenance of GSC properties in the tumor microenvironment remains unclear. In glioma, non-neoplastic cells create an inflammatory environment and subsequently mediate tumor progression and maintenance. Transcriptional factor CCAAT/enhancer-binding protein delta (CEBPD) is suggested to regulate various genes responsive to inflammatory cytokines, thus prompting us to investigate its role in regulating GSCs stemness after inflammatory stimulation. Stemness properties were analyzed by using spheroid formation. Oncomine and TCGA bioinformatic databases were used to analyze gene expression. Western blotting, quantitative real-time polymerase chain reaction, luciferase reporter assay, and chromatin immunoprecipitation assay were used to analyze proteins and gene transcript levels. The glioma tissue microarrays were used for CEBPD and PDGFA expression by immunohistochemistry staining. We first found that IL-1β promotes glioma spheroid formation and is associated with elevated CEBPD expression. Using microarray analysis, platelet-derived growth factor subunit A (PDGFA) was confirmed as a CEBPD-regulated gene that mediates IL-1β-enhanced GSCs self-renewal. Further analysis of the genomic database and tissue array revealed that the expression levels between CEBPD and PDGFA were coincident in glioma patient samples. This is the first report showing the activation of PDGFA expression by CEBPD through IL-1β treatment and a novel CEBPD function in maintaining the self-renewal feature of GSCs.

Sections du résumé

BACKGROUND BACKGROUND
The small population of glioma stem-like cells (GSCs) contributes to tumor initiation, malignancy, and recurrence in glioblastoma. However, the maintenance of GSC properties in the tumor microenvironment remains unclear. In glioma, non-neoplastic cells create an inflammatory environment and subsequently mediate tumor progression and maintenance. Transcriptional factor CCAAT/enhancer-binding protein delta (CEBPD) is suggested to regulate various genes responsive to inflammatory cytokines, thus prompting us to investigate its role in regulating GSCs stemness after inflammatory stimulation.
METHODS METHODS
Stemness properties were analyzed by using spheroid formation. Oncomine and TCGA bioinformatic databases were used to analyze gene expression. Western blotting, quantitative real-time polymerase chain reaction, luciferase reporter assay, and chromatin immunoprecipitation assay were used to analyze proteins and gene transcript levels. The glioma tissue microarrays were used for CEBPD and PDGFA expression by immunohistochemistry staining.
RESULTS RESULTS
We first found that IL-1β promotes glioma spheroid formation and is associated with elevated CEBPD expression. Using microarray analysis, platelet-derived growth factor subunit A (PDGFA) was confirmed as a CEBPD-regulated gene that mediates IL-1β-enhanced GSCs self-renewal. Further analysis of the genomic database and tissue array revealed that the expression levels between CEBPD and PDGFA were coincident in glioma patient samples.
CONCLUSION CONCLUSIONS
This is the first report showing the activation of PDGFA expression by CEBPD through IL-1β treatment and a novel CEBPD function in maintaining the self-renewal feature of GSCs.

Identifiants

pubmed: 31300060
doi: 10.1186/s12974-019-1535-z
pii: 10.1186/s12974-019-1535-z
pmc: PMC6626372
doi:

Substances chimiques

CEBPD protein, human 0
IL1B protein, human 0
Interleukin-1beta 0
Platelet-Derived Growth Factor 0
platelet-derived growth factor A 0
CCAAT-Enhancer-Binding Protein-delta 142662-43-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

146

Subventions

Organisme : Taipei Medical University Hospital
ID : TMU105-AE1-B07
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 105-2320-B-038-068-MY2
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 107-2320-B-038-068-002
Organisme : Ministry of Education
ID : The Featured Areas Research Center Program within the framework

Références

Cancer Res. 2005 Oct 1;65(19):8679-89
pubmed: 16204036
Cancer Cell. 2006 Apr;9(4):287-300
pubmed: 16616334
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
J Biol Chem. 2008 Nov 7;283(45):30919-32
pubmed: 18753137
Brain Res. 2009 Jun 5;1274:11-20
pubmed: 19362079
Neurobiol Aging. 2012 Feb;33(2):422.e11-25
pubmed: 21112127
Glia. 2011 Aug;59(8):1169-80
pubmed: 21446047
Cancer Cell. 2011 Apr 12;19(4):498-511
pubmed: 21481791
Oncogene. 2011 Dec 8;30(49):4901-9
pubmed: 21666710
Int Immunol. 2011 Nov;23(11):701-12
pubmed: 21937456
Cancer Cell. 2012 Jan 17;21(1):11-24
pubmed: 22264785
Trends Mol Med. 2013 Aug;19(8):460-73
pubmed: 23773831
Mol Neurobiol. 2015 Feb;51(1):370-82
pubmed: 24788683
Cell Death Dis. 2014 May 08;5:e1220
pubmed: 24810056
Carcinogenesis. 2015 Feb;36(2):177-85
pubmed: 25504149
Cancer Res. 2015 Jun 1;75(11):2337-48
pubmed: 25832656
Oncogene. 2016 Mar 24;35(12):1504-16
pubmed: 26165844
Sci Rep. 2015 Jul 13;5:12132
pubmed: 26166618
Mol Neurobiol. 2016 Aug;53(6):4173-4188
pubmed: 26208701
Oncotarget. 2015 Oct 13;6(31):31069-84
pubmed: 26307680
Mol Cancer Ther. 2015 Nov;14(11):2623-33
pubmed: 26358750
Mol Neurobiol. 2016 Nov;53(9):5912-5927
pubmed: 26510742
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Cancer Res. 2016 Feb 15;76(4):866-76
pubmed: 26744530
Clin Cancer Res. 2017 Jan 15;23(2):503-513
pubmed: 27435393
Cancer Res. 2016 Dec 15;76(24):7219-7230
pubmed: 27569208
Mol Neurobiol. 2018 Apr;55(4):3211-3223
pubmed: 28478507
Cardiovasc Res. 2017 Sep 1;113(11):1376-1388
pubmed: 28859294
J Exp Clin Cancer Res. 2017 Dec 28;36(1):193
pubmed: 29282077
Elife. 2017 Dec 29;6:
pubmed: 29286001
Mol Neurobiol. 2018 Aug;55(8):6927-6938
pubmed: 29363044
Redox Biol. 2018 Jun;16:104-112
pubmed: 29499563
J Biol Chem. 2018 Oct 12;293(41):15790-15800
pubmed: 30093408
Glia. 1995 Nov;15(3):257-63
pubmed: 8586462

Auteurs

Shao-Ming Wang (SM)

Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Hong-Yi Lin (HY)

Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan.

Yen-Lin Chen (YL)

Department of Pathology, Cardinal Tien Hospital, School of Medicine College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.

Tsung-I Hsu (TI)

Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Research Center of Neuroscience, Taipei Medical University, Taipei, Taiwan.
TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan.

Jian-Ying Chuang (JY)

Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan.

Tzu-Jen Kao (TJ)

Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Chiung-Yuan Ko (CY)

Graduate Institute of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. ko680108@tmu.edu.tw.
TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan. ko680108@tmu.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH